DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Quantbot Technologies LP

Quantbot Technologies LP reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 84.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 20,002 shares of the medical device company's stock after selling 108,680 shares during the period. Quantbot Technologies LP's holdings in DexCom were worth $1,556,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Versant Capital Management Inc purchased a new stake in shares of DexCom during the fourth quarter valued at $25,000. Private Trust Co. NA boosted its position in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after buying an additional 245 shares during the period. TD Private Client Wealth LLC grew its stake in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after acquiring an additional 167 shares in the last quarter. Larson Financial Group LLC increased its position in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after acquiring an additional 137 shares during the period. Finally, Heck Capital Advisors LLC bought a new stake in shares of DexCom during the fourth quarter valued at approximately $38,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insiders Place Their Bets

In related news, COO Jacob Steven Leach sold 14,076 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the transaction, the chief operating officer now owns 313,497 shares of the company's stock, valued at $22,063,918.86. This trade represents a 4.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael Jon Brown sold 13,000 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the completion of the sale, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. The trade was a 10.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is owned by insiders.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on DXCM shares. Citigroup lifted their target price on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research report on Tuesday, March 4th. Canaccord Genuity Group raised their target price on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Cfra Research upgraded DexCom to a "hold" rating in a report on Friday, March 21st. Finally, Morgan Stanley lifted their price target on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, DexCom has an average rating of "Moderate Buy" and an average target price of $99.82.

DexCom Stock Performance

Shares of DXCM traded down $1.73 during trading hours on Friday, reaching $67.74. 4,680,803 shares of the company traded hands, compared to its average volume of 4,055,857. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The business has a fifty day moving average price of $82.65 and a 200-day moving average price of $77.02. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $141.99. The stock has a market capitalization of $26.47 billion, a P/E ratio of 47.37, a P/E/G ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.